







Cognitive disorders in patients with chronic kidney disease: specificities of clinical assessment

Marion Pépin^{1,2}, Ana Carina Ferreira ^{3,4}, Mustafa Arici⁵, Maie Bachman⁶, Michelangelo Barbieri⁷, Inga Arune Bumblyte⁸, Sol Carriazo ⁹, Pilar Delgado¹⁰, Liliana Garneata¹¹, Konstantinos Giannakou¹², Olivier Godefroy¹³, Tomasz Grodzicki ¹⁴, Aleksandra Klimkiewicz-Mrowiec¹⁴, Justina Kurganaite ⁸, Sophie Liabeuf ^{15,16}, Carmen Antonia Mocanu¹¹, Giuseppe Paolisso^{7,17}, Goce Spasovski¹⁸, Evgueniy Stefanov Vazellov¹⁹, Davide Viggiano²⁰, Carmine Zoccali ^{21,22}, Ziad A. Massy^{1,23} and Andrzej Więcek²⁴; the CONNECT Action (Cognitive Decline in Nephro-Neurology European Cooperative Target)

¹Paris-Saclay University, UVSQ, Inserm, Clinical Epidemiology Team, Centre de Recherche en Epidémiologie et Santé des Populations (CESP), Villejuif, France, ²Department of Geriatrics, Ambroise Paré University Medical Center, APHP, Boulogne-Billancourt, France, ³Department of Nephrology, Centro Hospitalar e Universitário de Lisboa Central–Hospital Curry Cabral, Lisbon, Portugal, ⁴Department of Nephrology, Universidade Nova de Lisboa–Faculdade de Ciências Médicas, Lisbon, Portugal, ⁵Department of Internal Medicine, Division of Nephrology, Faculty of Medicine, Hacettepe University, Ankara, Turkey, ⁶Department of Health Technologies, School of Information Technologies, Tallinn University of Technology, Tallinn, Estonia, ⁷Department of Advanced Medical and Surgical Sciences, University of Campania “Luigi Vanvitelli”, Naples, Italy, ⁸Department of Nephrology, Lithuanian University of Health Sciences, Kaunas, Lithuania, ⁹Department of Nephrology and Hypertension, IIS–Fundacion Jimenez Diaz UAM, Madrid, Spain, ¹⁰Department of Neurology, Vall d’Hebron Hospital, Universitat Autònoma de Barcelona, Barcelona, Spain, ¹¹Department of Internal Medicine and Nephrology, “Carol Davila” University of Medicine and Pharmacy, “Dr Carol Davila” Teaching Hospital of Nephrology, Bucharest, Romania, ¹²Department of Health Sciences, School of Sciences, European University Cyprus, Nicosia, Cyprus, ¹³Department of Neurology, Amiens University Hospital, and Laboratory of Functional Neurosciences (UR UPJV 4559), Jules Verne University of Picardie, Amiens, France, ¹⁴Department of Internal Medicine and Gerontology, Jagiellonian University Medical College, Cracow, Poland, ¹⁵Department of Pharmacology, Amiens University Medical Center, Amiens, France, ¹⁶MP3CV Laboratory, EA7517, University of Picardie Jules Verne, Amiens, France, ¹⁷Mediterranea Cardiocentro, Naples, Italy, ¹⁸Department of Nephrology, Clinical Centre “Mother Theresa”, Saints Cyril and Methodius University, Skopje, North Macedonia, ¹⁹Dialysis Clinic of UMHAT “Alexandrovska”, Sofia Medical University, Sofia, Bulgaria, ²⁰Department of Nephrology, University of Campania “Luigi Vanvitelli”, Naples; BIOGEM, Ariano Irpino, Italy, ²¹Renal Research Institute, New York, NY, USA, ²²Associazione Ipertensione Nefrologia Trapianto Renale, Reggio Calabria, Italy, ²³Department of Nephrology, Ambroise Paré University Medical Center, APHP, Paris, France and ²⁴Department of Nephrology, Transplantation and Internal Medicine, Medical University of Silesia, Katowice, Poland,


Correspondence to: Marion Pépin; E-mail: marion.pepin@aphp.fr

ABSTRACT

Neurocognitive disorders are frequent among chronic kidney disease (CKD) patients. Identifying and characterizing cognitive impairment (CI) can help to assess the ability of adherence to CKD risk reduction strategy, identify potentially reversible causes of cognitive decline, modify pharmacotherapy, educate the patient and caregiver and provide appropriate patient and caregiver support. Numerous factors are associated with the development and progression of CI in CKD patients and various conditions can influence the results of cognitive assessment in

these patients. Here we review clinical warning signs that should lead to cognitive screening; conditions frequent in CKD at risk to interfere with cognitive testing or performance, including specificities of cognitive assessment in dialysis patients or after kidney transplantation; and available tests for screening and observed cognitive patterns in CKD patients.

Keywords: chronic kidney disease, clinical assessment, cognitive impairment, cognitive screening test, comprehensive battery



Downloaded from https://academic.oup.com/ndt/article/37/Supplement_2/ii24/6414898 by guest on 30 June 2023

INTRODUCTION

Chronic kidney disease (CKD) is a major public health problem with a high global incidence and prevalence, with important multisystemic complications leading to poor outcomes and high-cost treatments [1]. According to Kidney Disease: Improving Global Outcomes, CKD is defined as abnormalities of kidney structure or function present for >3 months with implications for health. The following criteria determine the diagnosis: decreased glomerular filtration rate (GFR; <60 mL/min/1.73 m²) or evidence of kidney damage such as albuminuria, tubular disorders, urine sediment abnormalities, structural deviations detected by histology or by imaging methods or a history of kidney transplantation. The reduction of GFR and increased albuminuria have a crucial role in the development of complications of CKD, and for this reason the disease is classified in five stages based on the GFR and risk levels are subclassified according to albuminuria levels [1]. CKD stages are associated with all-cause death, cardiovascular death, anaemia and bone and mineral disorders, among other complications [2]. The prevalence of CKD and cognitive impairment (CI) both increase with age. Cognitive changes occur early in CKD, when GFR decreases to <60 mL/min/1.73 m² or even before [3, 4].

The latest version of the Diagnostic and Statistical Manual of Mental Disorders defined neurocognitive disorder (NCD) as

primarily cognitive disorders, acquired and progressive [5]. Deterioration can affect one of the following six cognitive domains: complex attention, executive function, learning and memory, language, perceptual motor and social cognition. In mild NCD [corresponding to the state usually called ‘mild cognitive impairment’ (MCI)], the individual remains functionally independent, while in major NCD (subsumes the entity called ‘dementia’), CI is severe enough to compromise social and/or occupational functioning [6]. Cognitively impaired CKD patients often exhibit executive dysfunction that would be expected in vascular NCD, but CKD patients are also at higher risk of Alzheimer’s disease and mortality compared with the general population [7]. CI is associated with adverse outcomes and financial and social costs, including caregiver burden. CKD patients [especially when under renal replacement therapy (RRT)] could benefit from cognitive screening. Identifying CI in patients with CKD can help to assess the ability to adhere to a CKD risk reduction strategy, identify potentially reversible causes of dementia, modify pharmacotherapy, educate the patient and caregiver and provide appropriate patient and caregiver support. The potential benefits of screening likely outweigh the possible risks associated with identification, such as negative reaction to the diagnosis or stigma resulting from a diagnosis of dementia. We aim to review the specificities of clinical assessment for cognitive disorders in CKD patients: clinical warning signs that should lead to cognitive screening;

conditions frequent in CKD that may interfere with cognitive testing or performance, including specificities of cognitive assessment in dialysis patients or after kidney transplantation; and available tests for cognitive screening and observed cognitive patterns in CKD patients.

Warning signs of cognitive decline in CKD patients

Neurological complications frequently become clinically evident in advanced stages of the disease, therefore early detection and management of these conditions could reduce their impact at later stages [8]. Of interest, subjective cognitive complaints are not highly correlated with the presence of objective CI in end-stage renal disease (ESRD), highlighting the importance of periodic screening for early identification of CI that may lead to targeted interventions and timely discussions with the patient and his/her family [4, 9, 10]. Nephrologists and other clinicians may rely on their clinical judgement to obtain appropriate diagnoses. Of note, a previous study reported that mental impairment among haemodialysis (HD) patients was poorly recognized by healthcare providers/HD technicians, even though they reported spending an average of 47 min with each patient during each of the twice- or thrice-weekly treatments [11].

History taking and physical examination in conjunction with neuropsychological testing can accurately identify cognitive declines. Caregivers and family often notice cognitive deficits before they are apparent to clinicians. Therefore history taking from both the patient and caregiver/family is important for accurate reports on the onset, duration and severity of cognitive and behavioural deficits, the presence of functional impairments and other symptoms (e.g. sleep disturbance, depression, etc.) or other events including unexplained falls or confusion about medication [10, 12]. Of note, caregiver-reported sleep disturbances are frequently associated with early stages of dementia and might be considered as warning signs of cognitive deterioration [13]. The examiner should look for focal neurological deficits such as tremors, bradykinesia or rigidity suggestive of previous stroke and signs of parkinsonism [10].

Assessment of functionality in everyday activities and mobility performance metrics such as the gait speed assessment could also offer hints of cognitive decline. For instance, mobility performance metrics that involved multifaceted coordination between different parts of neuropsychology, such as cumulated posture duration and postural transition, could assist in discriminating those with and without CI [14]. CI suspicion may lead to a global and comprehensive patient assessment, especially screening for factors affecting cognitive performance. Older CKD patients might benefit from a nephrology-tailored comprehensive geriatric assessment including a cognitive assessment [15].

Conditions affecting cognitive assessment in CKD patients

Numerous factors can affect the results of cognitive assessment and cause deviations from the 'norm' in the psychometric definition. These factors should be considered when interpreting results in patients with CKD.

Demographic and psychosocial factors. Demographic factors such as lower education status, gender and age are key factors affecting the results of cognitive testing in the general population. Advancing age, a lower educational level and female gender are associated with poorer performance [15]. However, the impact of such factors on cognitive testing among CKD patients is limited [16]. Psychosocial factors including social support, socio-economic care and access to healthcare were also found to influence cognitive functioning in the general population. Similarly, data are limited regarding such factors and CI in this patient population. Of note, marital status, religious activity and employment were found to influence psychosocial adjustment to dialysis treatment and the risk for developing depression among dialysis patients [17].

Drug-related factors, sleep and depression. Multiple medications are required in CKD patients and the optimal dosing of several medications is unclear, therefore these patients could be more susceptible to potential adverse drug effects and interactions between medications [18]. Some medications are associated with CI in CKD patients, such as H1-receptor antagonists and opioids, probably because of their anticholinergic effect [19]. If possible, unnecessary or ineffective medications with central nervous system activity should be discontinued [19]. In addition, sleep disturbances are often underdiagnosed and undertreated in CKD patients, which can impact cognitive function (e.g. memory and concentration), leading to excessive daytime fatigue and sleepiness, impairing cognitive abilities directly [20]. Sleep-disordered breathing (sleep apnoea) was also found to affect cognitive testing in CKD patients [21]. Lastly, depression was found to be highly prevalent in dialysis patients compared with the general population, with most studies estimating that 20–30% of such individuals are depressed [22, 23]. Even though depression is relatively common in patients with all stages of CKD, it remains significantly underdiagnosed [20, 24]. Depression may influence the results of cognitive testing and hence assessment of depression and anxiety should be part of all neuropsychological evaluations [25].

Factors associated with impaired cognitive performance

Biologic intrinsic-related factors. Anaemia has been linked with cognitive deficiency in both CKD and the elderly [26]. This might be due to a decreased blood haemoglobin concentration that leads to reduced oxygen delivery to the brain, with a detrimental effect on brain metabolism, or could be because once the blood haemoglobin concentration declines, cerebral blood flow increases from normal to high levels, resulting in increased distribution of uraemic toxins to the brain. Of interest, early small-scale studies have shown cognitive improvement with the treatment of anaemia in CKD patients; however, it remains undetermined whether this is because of the improvement in the blood count or due to an independent effect of supplementation with erythropoiesis-stimulating agents (ESAs) [27]. This observation was not confirmed in more recent large-scale studies, where ESAs have not shown the expected beneficial clinical cognitive effects in CKD patients. Also, putative neurotoxins, including parathyroid hormone and by-products

of nitrogen metabolism, have also been mentioned as possible mediating factors of CI in CKD, but the underlying mechanisms are not well understood [28]. Interestingly, recent findings on the role of the glymphatic system, which clears the brain of protein waste products, primarily during sleep, offer pathophysiological hypotheses in CKD patients [13]. The link between uraemic toxins and cognitive disorders is described in detail in a parallel article in this supplement (Liabeuf *et al.*, NDT 2021). Evidence data about albuminuria as a risk factor for CI and dementia are also detailed in another article in this supplement (Hafez *et al.* NDT 2021).

Amino acids. Amino acids have a multifaceted physiological significance in addition to being the main building material in protein synthesis. Plasma levels of homocysteine, cysteine and cysteine sulfinic acid are elevated in uraemia and the percentages of protein-bound homocysteine and cysteine are higher in uraemic dialysis patients than in conservatively treated patients. Elevated homocysteine levels have been associated with impairment and decline on tests of cognitive function. Hyperhomocysteinaemia and low taurine levels are probably involved in the pathogenesis of concomitant cardiovascular and cerebrovascular diseases in patients with CKD. Supplementation with vitamin B (combinations containing B6, B12 and folic acid) in the Homocysteine Study to some extent corrected hyperhomocysteinaemia but had no effect on cognitive function [29]. The lack of a positive effect can be attributed to comorbidities [29]. Increased amounts of aspartate may contribute to age-related CI by facilitating excitotoxicity [30].

Vascular-related factors. Large prospective studies have indicated several vascular factors, including older age, hypertension, diabetes mellitus and dyslipidaemia, as risk factors for dementia in the general population [31]. Dialysis and CKD populations share most of these same risk factors for CI. Despite there is greater prevalence of traditional vascular risk factors [e.g. hypertension, diabetes mellitus, hyperlipidaemia, cigarette smoking, atrial fibrillation (AF) and myocardial infarction] and cardiovascular disease (CVD) among CKD patients, studies to date have failed to establish a direct link between any of these factors and the presence of cognitive dysfunction in patients with CKD [11, 28, 32, 33]. This implies that other factors may be implicated in the occurrence of CI.

A possible role has been suggested for novel vascular risk factors such as elevated levels of inflammatory mediators, which have been observed in CKD patients, highlighting the possibility of an association between inflammatory markers and all-cause dementia, as reported in the general population [34, 35]. Likewise, elevated levels of prostaglandin D2 synthase, a mediator of inflammation, could induce neural apoptosis in dialysis patients [36]. Higher C-reactive protein levels were also reported in dialysis patients [37] and have been linked to CI in the general population [38].

The significance of silent cerebrovascular disease is highlighted by studies that showed an association between CI and silent brain infarction, which was most commonly attributable to subcortical lacunar infarcts in the general population [39]. Silent brain infarction has been shown to be an

independent risk factor for future cerebral and vascular morbidity and incident dementia in both CKD/dialysis patients and the general population [39–41]. Previous magnetic resonance imaging studies have indicated that clinically silent white matter hyperintensities of presumed vascular origin appear in $\geq 50\%$ of patients with CKD [41, 42] and relate to deficits in the cognitive domains of executive function and processing speed, suggesting a subcortical, vascular pattern of CI. Notably, established risk factors for white matter disease in CKD include advanced age, hypertension and smoking [41]. Other lesions may be involved besides lacunar infarcts and white matter hyperintensities, such as brain microbleeds or atrophy related to cerebral small vessel disease.

Cardiac arrhythmias. CVDs frequently occur in CKD patients [43]. CKD is combined with haemodynamic changes, which might further contribute to the negative changes in cardiac structure. In particular, it has been reported that 50% of all patients affected by CKD Stages 4 and 5 have CVD and cardiovascular mortality accounts for almost 50% of all deaths in CKD patients (Stages 4 and 5) compared with 26% of age-matched healthy control subjects [43]. Focusing on myocardial alterations, left ventricular hypertrophy (LVH) is present in almost 30% of CKD patients, a prevalence that increases up to 70–80% in CKD Stage 5 patients [44]. LVH was associated with incident dementia due to the strong association with increased systemic blood pressure, followed by impaired ventricular filling, left ventricular diastolic dysfunction, whole body hypoperfusion as well as myocardial structural changes such as a dilated atrial chamber, with an enhanced probability to develop AF [45]. Such negative cardiac structural changes are often associated with a high ventricular rate [46], which again is responsible for brain hypoperfusion and sudden death. Among the cardiac arrhythmias, AF is most common, estimated to occur in 44% of CKD (Stages 3–5) patients [47]. AF is one of the treatable cognitive risk factors in CKD. Direct evidence of the strong relationship between AF and cognitive decline is also provided by the evidence that anticoagulation and ablation, but not anti-aggregation, are helpful therapeutic tools for treating AF and preventing cognitive decline [48].

Pulse wave velocity. Arterial stiffness can cause microvascular damage in the brain due to an increased impact of pulsatility on the microvasculature, which possibly alters brain structure or cognitive functioning. Several studies in CKD patients have shown an association between increased pulse wave velocity and CI (global cognition or executive dysfunction), pointing to the role of large artery damage in this complex process [49].

Specificities of cognitive assessment for patients under RRT

Dialysis. One important aspect for clinicians and researchers involved in cognitive testing of patients with CKD is the timing: when, during the day, should a cognitive test be administered? This question is especially crucial for HD patients. There is a theoretical risk that administering tests during the dialysis session may lead to altered performance due to the lack of privacy,

the ongoing extracorporeal treatment (with modifications in electrolyte and water content of the plasma), the forced immobilization, the psychologically stressful situation and the effect of accumulated toxins. Furthermore, these variables make comparisons with a control population more difficult, as non-HD control subjects are tested in completely different conditions.

To empirically test this problem, Murray *et al.* [50] observed that the Mini-Mental State Examination (MMSE) score was reduced by 1 point (4%) when administered before HD compared with the score achieved 1 h after treatment or the day after [50]. This result has been known since the 1970s and confirmed several times [51]. Unsurprisingly, the lower MMSE scores do not improve during the first hour of HD [50, 52]. Likewise, imaging studies [53] and electroencephalogram (EEG) records [54] have shown variations in brain activity according to the timing of the dialysis session.

This timing parameter seems less problematic regarding cognitive testing in peritoneal dialysis (PD), due to it being an at-home treatment and the frequent dialytic exchanges (often on the order of two to three per day, every day). Indeed, one major difference between HD and PD is the intermittent nature of the HD treatment compared with the almost continuous PD treatment. An EEG study confirmed that PD brain activity is more stable compared with the great changes occurring before and after HD (with better EEG after HD) [54]. Therefore, studies adopt an off-dialysis timing (with an interval of at least 2 h from the last session) [55]. New methods of HD (such as nocturnal HD or the use of a cooled dialysate) are expected to reduce the burden of sessions on neurocognitive function and quality of life.

These data suggest that the cognitive performance in HD patients is not stable and may constantly decrease as a function of the elapsed time from the last dialysis session. This may greatly impinge on interpretation of the results. Therefore we recommend testing patients at least 1 h after the HD session, particularly if a control group without HD is used. The testing time for PD should be the same as for the general population. We also recommend establishing appropriate timing in research studies in case patients with CKD are included.

Kidney transplantation. Cognitive function has been shown to improve after kidney transplantation, specifically in psychomotor speed, attention, visual planning, learning and memory and abstract thinking [56]. Nevertheless, CI remains more frequent in kidney transplant (KT) patients than in the general population and is associated with frailty measured using the physical frailty phenotype developed [57, 58]. Frail KT recipients are at a higher risk of immunosuppression intolerance and mortality than non-frail patients [58]. Post-KT frailty and cognitive performance are likely dynamic. On the one hand, frailty initially worsens in the first month post-KT, but then improves by 3 months post-KT; on the other hand, cognitive performance, assessed by the modified MMSE (3MSE), tends to improve in the first 3 months post-KT [57, 58]. More research is needed to differentiate if post-KT issues, like wound healing, immunosuppression and infections, may affect the reversal of frailty and CI after KT.

Of note, in animal models, stress and corticosteroids are associated with memory impairment and both reversible and irreversible changes in the hippocampus. Clinical studies observed that exposure to exogenous corticosteroids can change mood and declarative memory, but a negative effect on cognition was modest [59]. Psychopathological signs frequently observed indicate that corticosteroids may also induce functional disorder of additional brain regions (e.g. frontal and temporal lobes), which are important for cognitive and emotional processing [60]. In order to minimize the impact of high-dose steroids and operative procedures on cognition, we recommend performing an assessment at least 1 month after transplantation.

Perceived and measured cognition in KT patients differs. In 157 KT patients assessed by trained medical personnel, perceived cognition scores weakly correlated with Montreal Cognitive Assessment (MoCA) scores [61]. Therefore, as in other CKD patients, efficient cognitive screening in KT patients relies on objective screening tests. However, it is still not fully clear which screening tool should be used. Recent studies observed discrepancies in the prevalence of CI in KT patients, probably because the tests were different (MoCA, DemTect tool) [62].

Calcineurin inhibitors (CNIs) have a known side effect of neurotoxicity [63]. A small study observed that attention and working memory were impaired in KT patients treated with sirolimus or tacrolimus, while performance of cyclosporine-treated subjects was similar to healthy volunteer controls. Long-term effects of CNI on cognition and physiopathology are not well understood [63]. Further studies may establish the optimal timing for cognitive assessment after KT and identify an optimal screening test in this specific population.

Screening tests

Today, most scientific societies, including nephrology, recommend cognitive assessment in individuals with cognitive complaints and in individuals whose caregivers notice symptoms that may indicate the presence of CI, especially when there are difficulties in daily functioning. Various screening tests are commonly used in daily clinical practice to assess cognitive status [64] (see Table 1).

There is no consensus on which screening instrument should be used to identify NCD (major or mild) in people with CKD. Rather, the screening methods used reflect the availability of tests in a given language or the habits of the examinees.

In clinical practice, two main screening tests of CI are used, the MMSE and, more recently, the MoCA. As in other diseases [65], the superiority of the MoCA, which also assesses executive functions, and is especially sensitive to brain dysfunction compared with the MMSE, has been examined in several studies in CKD patients. Focusing on the few studies using a comprehensive neuropsychological battery as a gold standard and receiver operating characteristics curve analysis, the area under the curve (AUC) did not significantly differ across tests [66, 67]. This indicates that the sensitivity of both screening tests does not differ greatly, although the small to moderate sample sizes require careful conclusion. From our point of view, the important conclusion from these studies is that the sensitivity of both


Table 1. Examples of psychometric tests used in CKD patients

Examples of tests	Details of test	Function assessed	Use in CKD
Global cognition			
MMSE	30-point test (orientation, attention and calculation, memory, language and visuospatial abilities)	Screening of global CI	Yes
MoCA	30-point test (visuospatial abilities, executive functions, memory, attention, language, abstract reasoning and orientation)	Screening of global CI (including executive functions)	Yes
CDT	Non-verbal test. The patient is asked to draw a clock face and mark the hours and then draw the hands to indicate a particular time	Executive functions, visuospatial and visuoconstructional functioning	Yes
Language			
Boston Naming Test	Name objects shown in 60 black-and-white line drawings. Items are ordered according to their ability to be named, which is correlated with their frequency	Confrontation naming	Yes
Visuospatial and constructive abilities			
Cancellation test	Lines, circles, letters bells or stars are drawn in random positions on a sheet of paper (A4) and presented to patient, who is asked to cancel or cross out the target	Visual neglect, response inhibition, motor perseveration and attention	Yes
Judgement of line orientation	30-item test in which the patient is asked to match two angled lines to a set of 11 lines that are arranged in a semi-circle and separated 18 degrees from each other	Visuospatial perception	Yes
Rey-Osterrieth complex figure test (copying)	Patient is asked to copy a complex geometrical figure	Complex visuospatial constructional ability	Yes
Wechsler Adult Intelligence Scale (WAIS) block design	Timed subtest of the WAIS. Identical blocks with surfaces of solid red, surfaces of solid white and surfaces that are half-red and half-white are presented to the patient. The patient is asked, using an increasing number of blocks, to replicate a pattern that the test administrator presents to the patient	Visuospatial and organizational abilities and processing speed	Yes
Episodic memory			
Verbal memory			
Free and Cued Selective Recall Test (FCRST)	The test is based on 12 pictorial stimuli. The patient is asked to identify pictured items (e.g. grapes and vest) in response to category cues (fruit and clothing). In the test phase, subjects are asked to recall the items they learned (free recall). The category cues are used to prompt recall of items not retrieved by free recall	Memory (includes assessment of retrieval processes)	Yes
California Verbal Learning Test	Patient is asked to recall List A (16 words) ≥ 5 times. List B (interference, 16 words) is administered after List A for one trial. Short-delay free recall and cued recall are administered after List B. A long delay follows the short-delay recalls, followed by non-verbal testing	Memory (includes assessment of proactive interference)	Yes
Visuospatial memory			
Baddeley Door Test	The patient views photographs of 12 doors for 3 s each. Immediately thereafter, the patient tries to identify the door from the study list among 12 arrays of 4 doors each	Visual memory	Yes
Rey-Osterrieth Complex Figure Test (3 min recall)	The patient is asked to reproduce from memory the complex geometric figure he copied after a short delay (3 min) and then a long delay (30 min)	Visual memory	Yes
Executive functions and action speed			
TMT	Part A requires an individual to draw lines sequentially connecting 25 encircled numbers distributed on a sheet of paper. In Part B the patient must alternate between numbers and letters (1-A-2-B-3-C)	Visuomotor speed, visual attention (TMT Part A) and task switching (TMT Part B)	Yes
The Stroop Colour and Word Test	First, the subject is required to read names of colours printed in black ink. Second, the subject names different colour patches. Third, he/she is required to name the colour of the ink instead of reading the word (colour words are printed in an inconsistent colour ink)	Inhibition of cognitive interference	Yes
Semantic and literal fluency	The patient is given 1 min to produce as many words as possible within a semantic category or starting with a given letter	Lexico-semantic knowledge, lexical retrieval ability and executive control ability	Yes

Continued

Table 1. Continued

Examples of tests	Details of test	Function assessed	Use in CKD
WAIS Digit Symbol Substitution subtest	Timed subtest of the WAIS. The test involves a key consisting of numbers (1–9), each paired with a unique symbol. Below the key is a series of numbers (1–9) in random order. The subject is then allowed 90 s to fill in the corresponding symbol for each number	Processing speed, working memory, visuospatial processing and attention	Yes
Wisconsin Card Sorting Test	The subject is given a set of four stimulus cards, each different from the other in terms of colour, shape or number. The participant is asked to accurately sort every response card with one of four stimulus cards but not how to match. The administrator provides simple feedback (right or wrong) based on a predetermined rule	Abstract reasoning, mental flexibility and problem solving	Yes
Inventory of the Behavioural Dysexecutive Syndrome	Structured interview of an individual assessing changes relative to previous behaviour in 12 domains	Behavioural disorders (apathy, impulsivity, psychomotor instability, anosognosia etc.)	Yes



Collaboration between nephrologists, neurologists, neuropsychologists, geriatricians, and general practitioners

FIGURE 1: Integrating CKD in NCDs.

screening tests is usually <80%, which appears to be moderate [66–68].

Regarding other screening tests, the Clock Drawing Test (CDT), the digit span backward and the fist-edge-palm test showed similar performance in identifying MCI in this population when compared with the MoCA ($\leq 24/30$ patients) [69]. In a recently published study, Drew *et al.* [67] compared the predictive ability of MMSE, 3MSE, MoCA, Trail Making Test (TMT) Part B, Mini-Cog Test and the Digit Symbol Substitution Test performance for identifying severe CI among patients with HD. The MoCA had the highest overall predictive

ability for severe CI (AUC 0.81). The score of $\leq 21/30$ patients had a sensitivity of 86% and specificity of 55% for severe impairment, with a negative predictive value of 91%. The TMT Part B and Digit Symbol Substitution Test also performed reasonably well (AUCs 0.73 and 0.78, respectively). The other tests had lower predictive performances.

Self-reported cognitive assessment methods (e.g. MAC-Q) are also available, but these are based primarily on observations of memory deficits and may not have sufficient diagnostic sensitivity in people with CKD. Despite some limitations, self-reported assessment of instrumental activities of daily living

remains useful in determining the cognitive function of a patient. In case it is not possible to examine the patient in person, it is advisable to use tools that allow for assessment by the caregiver. The AD8 scale or Informant Questionnaire on Cognitive Decline in the Elderly are recommended. Even if physicians do not frequently use these modalities in daily practice, they can be useful for epidemiologic studies. It is worth noting that most of these cognitive tests were developed and validated in the ageing population, affected by physiological decline in both brain and renal function.

From a practical point of view, we propose using one of the main screening tests (the MoCA or MMSE) with education- (both tests) and age-adjusted (MoCA) cut-offs computed using normative data from the population of the country. Future studies are required to identify an optimal screening test and cut-off for CKD patients.

Cognitive pattern in CKD patients

The diagnosis of mild NCD and mild dementia (which is the present targeted stage of diagnostics) requires comprehensive neuropsychological assessment performed by a neuropsychologist. In addition to a positive diagnosis, comprehensive assessment determines the cognitive pattern, which constitutes a central cue for the aetiological diagnosis. The choice of tests composing the battery is determined by the clinical context in order to improve sensitivity. It usually includes tests assessing instrumental functions (language, visuospatial and constructive abilities), episodic memory, action speed and executive functions assessed both at the cognitive (i.e. tests) and behavioural (i.e. semistructured heteroquestionnaires that include social cognition) levels. Such a battery is usually not used for diagnostic purposes in patients with clear impairment on screening tests (e.g. MMSE <18 or MoCA <14); it should be interpreted using country-related norms and specific procedures to improve diagnostic accuracy [70].

The pattern of CI in CKD is not definitely established. Berger *et al.* [4] systematically reviewed CI in CKD patients [estimated GFR (eGFR) <60 mL/min/1.73 m²] without RRT, including 44 cross-sectional and cohort studies with 51 590 participants in the final meta-analysis. Cognitive domains were not assessed with the same frequency in the studies: attention and action speed (referred to as 'orientation and attention' in the article; 28 studies), global cognition (25 studies), memory (16 studies), executive functions (15 studies), construction and motor praxis (11 studies), language (9 studies), concept formation and reasoning (6 studies) and perception (1 study). CKD patients (eGFR <60 mL/min/1.73 m²) performed worse than control groups in almost all cognitive domains except perception, construction and motor praxis. The study of Puy *et al.* [66] formally assessed test sensitivity in 40 patients and showed that four of the tests had a Cohen's *d* index ≥ 0.8 : TMT Part B, Digit Symbol Substitution Test, literal fluency and the groupe de reflexion pour l'évaluation des fonctions eXécutives (GREFEX) inventory of the behavioural dysexecutive syndrome. This is accounted for by the cognitive pattern with prominent impairment of action speed (also called psychomotor speed or processing speed) and cognitive and behavioural executive

functions. Anxiety and depression symptoms were also common [66].

Cognitive decline occurs early in CKD and its frequency has been observed with different rates across cognitive domains according to GFR decline in these cross-sectional studies [4]. Interestingly, in studies assessing cognitive function in HD patients, the frequency of every cognitive domain measurement has the same ranges as in patients without RRT, from the most frequent (with the most frequent test used): orientation and attention (with TMT Parts A and B), global cognition (MMSE), memory (Wechsler Memory Scale), construction and motor (Clock and Grooved Peg Board), executive function (Stroop test), concept and reasoning (progressive matrices), language (Hopkins Verbal Learning Test) and perception (Haltstead-Reitan Neuropsychological Battery) [71]. Executive functions and orientation and attention are the most frequently affected domains in HD patients, even if their performance is poorer than controls in other domains [51, 71]. The cognitive pattern seems to be different in PD patients, with less impaired executive function [55].

These studies converge towards a prominent impairment of three neuropsychological domains (action speed, cognitive and behavioural executive functions) followed by impairment of language and episodic memory [4, 51, 66, 71]. Such a cognitive pattern is close to that of the two leading causes of CI, vascular CI and Alzheimer's disease. Based on this review, future research may establish test sensitivity and cognitive patterns in a large and representative population of CKD patients, including full aetiological workup.

CONCLUSION

Cognitive disorders are a frequent issue in patients with CKD. Clinical assessment of CI in this population involves many specific conditions, as can be seen in Figure 1. Although much is known, gaps in knowledge remain in this area. Further research needs to be done, including the establishment of cognitive test sensitivity for the CKD and KT populations, a description of cognitive patterns and the establishment of optimal timing for cognitive assessment in dialysis patients and after KT, among others. Further research may be useful to provide guidelines for clinicians, as comprehensive clinical assessment and aetiological workup will help to provide suitable therapeutic management taking into consideration CKD specificities.

ACKNOWLEDGEMENTS

The authors would like to thank Prof. Giovambattista Capasso, acting chair of Cognitive Decline in Nephro-Neurology: European Cooperative Target (CONNECT) Action and members of COST Action for their support.

FUNDING

This article is published as part of a supplement financially supported by the COST Action CA19127-Cognitive Decline in Nephro-Neurology: European Cooperative Target (CONNECT).

CONFLICT OF INTEREST STATEMENT

None declared. The results presented in this article have not been published previously in whole or part, except in abstract format.

APPENDIX

CONNECT collaborators are

Giovambattista Capasso; Alexandre Andrade; Maia Bachmann; Inga Bumblyte; Adrian Constantin Covic; Pilar Delgado; Nicole Endlich; Andreas Engvig; Denis Fouque; Casper Franssen; Sebastian Frische; Liliana Garneata; Loreto Gesualdo; Konstantinos Giannakou; Dimitrios Goumenos; Ayşe Tuğba Kartal; Laila-Yasmin Mani; Hans-Peter Marti; Christopher Mayer; Rikke Nielsen; Vesna Pšić; Merita Rroji (Molla); Giorgos Sakkas; Goce Spasovski; Kate I. Stevens; Evgeniy Vazellov; Davide Viggiano; Lefteris Zacharia; Ana Carina Ferreira; Jolanta Malyszko; Ewout Hoorn; Andreja Figurek; Robert Unwin; Carsten A. Wagner; Christoph Wanner; Annette Bruchfeld; Marion Pepin; Andrzej Wiećek; Dorothea Nitsch; Ivo Fridolin; Gaye Hafez; Maria José Soler; Michelangelo Barbieri; Bojan Batinić; Laura Carrasco; Sol Carriazo; Ron Gansevoort; Gianvito Martino; Francesco Mattace Raso; Ionut Nistor; Alberto Ortiz; Giuseppe Paolisso; Daiva Rastenytė; Gabriel Stefan; Gioacchino Tedeschi; Ziad A. Massy; Boris Bikbov; Karl Hans Endlich; Olivier Godefroy; Jean-Marc Chillon; Anastassia Kossioni; Justina Kurganaite; Norberto Perico; Giuseppe Remuzzi; Tomasz Grodzicki; Francesco Trepiccione; Carmine Zoccali; Mustafa Arici; Peter Blankestijn; Kai-Uwe Eckardt; Danilo Fliser; Eugenio Gutiérrez Jiménez; Maximilian König; Ivan Rychlik; Michela Deleidi; George Reusz.

REFERENCES

1. Levey AS, Coresh J. Chronic kidney disease. *Lancet* 2012; 379: 165–180
2. Quinn MP, Cardwell CR, Kee F *et al.* The finding of reduced estimated glomerular filtration rate is associated with increased mortality in a large UK population. *Nephrol Dial Transplant* 2011; 26: 875–880
3. Murray AM. Cognitive impairment in the aging dialysis and chronic kidney disease populations: an occult burden. *Adv Chronic Kidney Dis* 2008; 15: 123–132
4. Berger I, Wu S, Masson P *et al.* Cognition in chronic kidney disease: a systematic review and meta-analysis. *BMC Med* 2016; 14: 206
5. Sachdev PS, Mohan A, Taylor L *et al.* DSM-5 and mental disorders in older individuals: an overview. *Harv Rev Psychiatry* 2015; 23: 320–328
6. Hugo J, Ganguli M. Dementia and cognitive impairment: epidemiology, diagnosis, and treatment. *Clin Geriatr Med* 2014; 30: 421–442
7. McAdams-DeMarco MA, Daubresse M, Bae S *et al.* Dementia, Alzheimer's disease, and mortality after hemodialysis initiation. *Clin J Am Soc Nephrol* 2018; 13: 1339–1347
8. Arnold R, Issar T, Krishnan AV *et al.* Neurological complications in chronic kidney disease. *JRSM Cardiovasc Dis* 2016; 5: 2048004016677687
9. Leinau L, Murphy TE, Bradley E *et al.* Relationship between conditions addressed by hemodialysis guidelines and non-ESRD-specific conditions affecting quality of life. *Clin J Am Soc Nephrol* 2009; 4: 572–578
10. Kurella Tamura M, Yaffe K. Dementia and cognitive impairment in ESRD: diagnostic and therapeutic strategies. *Kidney Int* 2011; 79: 14–22
11. Sehgal AR, Grey SF, DeOreo PB *et al.* Prevalence, recognition, and implications of mental impairment among hemodialysis patients. *Am J Kidney Dis* 1997; 30: 41–49

12. Viggiano D, Wagner CA, Blankestijn PJ *et al.* Mild cognitive impairment and kidney disease: clinical aspects. *Nephrol Dial Transplant* 2020; 35: 10–17
13. Viggiano D, Wagner CA, Martino G *et al.* Mechanisms of cognitive dysfunction in CKD. *Nat Rev Nephrol* 2020; 16: 452–469
14. Zhou H, Al-Ali F, Wang C *et al.* Harnessing digital health to objectively assess cognitive impairment in people undergoing hemodialysis process: the impact of cognitive impairment on mobility performance measured by wearables. *PLoS One* 2020; 15: e0225358
15. Verghese J, Wang C, Lipton RB *et al.* Motoric cognitive risk syndrome and the risk of dementia. *J Gerontol A Biol Sci Med Sci* 2013; 68: 412–418
16. Pereira AA, Weiner DE, Scott T *et al.* Cognitive function in dialysis patients. *Am J Kidney Dis* 2005; 45: 448–462
17. Kimmel PL. Depression in patients with chronic renal disease: what we know and what we need to know. *J Psychosom Res* 2002; 53: 951–956
18. Liabeuf S, Laville M. Drug prescription in patients with chronic kidney disease: a true challenge. *Nephrol Dial Transplant* 2021; 36: 385–386
19. Kurella Tamura M, Larive B, Unruh ML *et al.* Prevalence and correlates of cognitive impairment in hemodialysis patients: the Frequent Hemodialysis Network trials. *Clin J Am Soc Nephrol* 2010; 5: 1429–1438
20. Iliescu EA, Coe H, McMurray MH *et al.* Quality of sleep and health-related quality of life in haemodialysis patients. *Nephrol Dial Transplant* 2003; 18: 126–132
21. Kang EW, Abdel-Kader K, Yabes J *et al.* Association of sleep-disordered breathing with cognitive dysfunction in CKD stages 4–5. *Am J Kidney Dis* 2012; 60: 949–958
22. Finkelstein FO, Finkelstein SH. Depression in chronic dialysis patients: assessment and treatment. *Nephrol Dial Transplant* 2000; 15: 1911–1913
23. Wang WL, Liang S, Zhu FL *et al.* The prevalence of depression and the association between depression and kidney function and health-related quality of life in elderly patients with chronic kidney disease: a multicenter cross-sectional study. *Clin Interv Aging* 2019; 14: 905–913
24. Al-Hihi E, Awad A, Hagedorn A. Screening for depression in chronic hemodialysis patients. *Mo Med* 2003; 100: 266–268
25. Agganis BT, Weiner DE, Giang LM *et al.* Depression and cognitive function in maintenance hemodialysis patients. *Am J Kidney Dis* 2010; 56: 704–712
26. Eisenstaedt R, Penninx BW, Woodman RC. Anemia in the elderly: current understanding and emerging concepts. *Blood Rev* 2006; 20: 213–226
27. Cerami A, Brines M, Ghezzi P *et al.* Neuroprotective properties of epoetin alfa. *Nephrol Dial Transplant* 2002; 17(Suppl 1): 8–12
28. Kurella M, Chertow GM, Fried LF *et al.* Chronic kidney disease and cognitive impairment in the elderly: the health, aging, and body composition study. *J Am Soc Nephrol* 2005; 16: 2127–2133
29. Brady CB, Gaziano JM, Cxypoliski RA *et al.* Homocysteine lowering and cognition in CKD: the Veterans Affairs homocysteine study. *Am J Kidney Dis* 2009; 54: 440–449
30. Hu R, Huang D, Tong J *et al.* Aspartic acid in the hippocampus: a biomarker for postoperative cognitive dysfunction. *Neural Regen Res* 2014; 9: 143–152
31. DeCarli C. The role of cerebrovascular disease in dementia. *Neurologist* 2003; 9: 123–136
32. Yaffe K, Ackerson L, Kurella Tamura M *et al.* Chronic kidney disease and cognitive function in older adults: findings from the chronic renal insufficiency cohort cognitive study. *J Am Geriatr Soc* 2010; 58: 338–345
33. Stam F, van Guldener C, Becker A *et al.* Endothelial dysfunction contributes to renal function-associated cardiovascular mortality in a population with mild renal insufficiency: the Hoorn study. *J Am Soc Nephrol* 2006; 17: 537–545
34. Schmidt R, Schmidt H, Curb JD *et al.* Early inflammation and dementia: a 25-year follow-up of the Honolulu-Asia Aging Study. *Ann Neurol* 2002; 52: 168–174
35. Teunissen CE, van Bostel MP, Bosma H *et al.* Inflammation markers in relation to cognition in a healthy aging population. *J Neuroimmunol* 2003; 134: 142–150
36. Maesaka JK, Palaia T, Fishbane S *et al.* Contribution of prostaglandin D2 synthase to progression of renal failure and dialysis dementia. *Semin Nephrol* 2002; 22: 407–414
37. Fine A. Relevance of C-reactive protein levels in peritoneal dialysis patients. *Kidney Int* 2002; 61: 615–620

38. Kurella Tamura M, Tam K, Vittinghoff E *et al*. Inflammatory markers and risk for cognitive decline in chronic kidney disease: the CRIC study. *Kidney Int Rep* 2017; 2: 192–200
39. Vermeer SE, Prins ND, den Heijer T *et al*. Silent brain infarcts and the risk of dementia and cognitive decline. *N Engl J Med* 2003; 348: 1215–1222
40. Vermeer SE, Den Heijer T, Koudstaal PJ *et al*. Incidence and risk factors of silent brain infarcts in the population-based Rotterdam Scan Study. *Stroke* 2003; 34: 392–396
41. Nakatani T, Naganuma T, Uchida J *et al*. Silent cerebral infarction in hemodialysis patients. *Am J Nephrol* 2003; 23: 86–90
42. Kim CD, Lee HJ, Kim DJ *et al*. High prevalence of leukoaraiosis in cerebral magnetic resonance images of patients on peritoneal dialysis. *Am J Kidney Dis* 2007; 50: 98–107
43. Jankowski J, Floege J, Fliser D *et al*. Cardiovascular disease in chronic kidney disease: pathophysiological insights and therapeutic options. *Circulation* 2021; 143: 1157–1172
44. Di Lullo L, Gorini A, Russo D *et al*. Left ventricular hypertrophy in chronic kidney disease patients: from pathophysiology to treatment. *Cardiorenal Med* 2015; 5: 254–266
45. Norby FL, Chen LY, Soliman EZ *et al*. Association of left ventricular hypertrophy with cognitive decline and dementia risk over 20 years: the Atherosclerosis Risk in Communities-Neurocognitive Study (ARIC-NCS). *Am Heart J* 2018; 204: 58–67
46. Soglietto A, Scarsoglio S, Ridolfi L *et al*. Higher ventricular rate during atrial fibrillation relates to increased cerebral hypoperfusions and hypertensive events. *Sci Rep* 2019; 9: 3779
47. Khouri Y, Stephens T, Ayuba G *et al*. Understanding and managing atrial fibrillation in patients with kidney disease. *J Atr Fibrillation* 2015; 7: 1069
48. Diener HC, Hart RG, Koudstaal PJ *et al*. Atrial fibrillation and cognitive function: JACC review topic of the week. *J Am Coll Cardiol* 2019; 73: 612–619
49. Zijlstra LE, Trompet S, Jukema JW *et al*. Association of cardiovascular structure and function with cerebrovascular changes and cognitive function in older patients with end-stage renal disease. *Aging (Albany NY)* 2020; 12: 1496–1511
50. Murray AM, Pederson SL, Tupper DE *et al*. Acute variation in cognitive function in hemodialysis patients: a cohort study with repeated measures. *Am J Kidney Dis* 2007; 50: 270–278
51. Schneider SM, Malecki AK, Müller K *et al*. Effect of a single dialysis session on cognitive function in CKD5D patients: a prospective clinical study. *Nephrol Dial Transplant* 2015; 30: 1551–1559
52. Drew DA, Tighiouart H, Scott TM *et al*. Cognitive performance before and during hemodialysis: a randomized cross-over trial. *Nephron Clin Pract* 2013; 124: 151–158
53. Schaier M, Wolf RC, Kubera K *et al*. Vasogenic brain edema during maintenance hemodialysis: preliminary results from tract-based spatial statistics and voxel-based morphometry. *Clin Neuroradiol* 2021; 31: 217–224
54. Buoncristiani U, Alberti A, Gubbiotti G *et al*. Better preservation of cognitive faculty in continuous ambulatory peritoneal dialysis. *Perit Dial Int* 1993; 13: 202–205
55. Kalirao P, Pederson S, Foley RN *et al*. Cognitive impairment in peritoneal dialysis patients. *Am J Kidney Dis* 2011; 57: 612–620
56. Gupta A, Lepping RJ, Yu AS *et al*. Cognitive function and white matter changes associated with renal transplantation. *Am J Nephrol* 2016; 43: 50–57
57. Chu NM, Gross AL, Shaffer AA *et al*. Frailty and changes in cognitive function after kidney transplantation. *J Am Soc Nephrol* 2019; 30: 336–345
58. McAdams-DeMarco MA, Chu NM, Segev DL. Frailty and long-term post-kidney transplant outcomes. *Curr Transplant Rep* 2019; 6: 45–51
59. Prado CE, Crowe SF. Corticosteroids and cognition: a meta-analysis. *Neuropsychol Rev* 2019; 29: 288–312
60. Brown ES, Vera E, Frol AB *et al*. Effects of chronic prednisone therapy on mood and memory. *J Affect Disord* 2007; 99: 279–283
61. Gupta A, Thomas TS, Klein JA *et al*. Discrepancies between perceived and measured cognition in kidney transplant recipients: implications for clinical management. *Nephron* 2018; 138: 22–28
62. Nöhre M, Bauer-Hohmann M, Klewitz F *et al*. Prevalence and correlates of cognitive impairment in kidney transplant patients using the DemTect—results of a KTx360 substudy. *Front Psychiatry* 2019; 10: 791
63. Jurgensen A, Qannus AA, Gupta A. Cognitive function in kidney transplantation. *Curr Transplant Rep* 2020; 7: 145–153
64. Patnode CD, Perdue LA, Rossom RC *et al*. Screening for cognitive impairment in older adults: updated evidence report and systematic review for the US Preventive Services Task Force. *JAMA* 2020; 323: 764–785
65. Siqueira GSA, Hagemann PMS, Coelho DS *et al*. Can MoCA and MMSE be interchangeable cognitive screening tools? A systematic review. *Gerontologist* 2019; 59: e743–e763
66. Puy L, Bugnicourt JM, Liabeuf S *et al*. Cognitive impairments and dysexecutive behavioral disorders in chronic kidney disease. *J Neuropsychiatry Clin Neurosci* 2018; 30: 310–317
67. Drew DA, Tighiouart H, Rollins J *et al*. Evaluation of screening tests for cognitive impairment in patients receiving maintenance hemodialysis. *J Am Soc Nephrol* 2020; 31: 855–864
68. Tiffin-Richards FE, Costa AS, Holschbach B *et al*. The Montreal Cognitive Assessment (MoCA) – a sensitive screening instrument for detecting cognitive impairment in chronic hemodialysis patients. *PLoS One* 2014; 9: e106700
69. Paraizo MDA, Almeida ALM, Pires LA *et al*. Montreal Cognitive Assessment (MoCA) screening mild cognitive impairment in patients with chronic kidney disease (CKD) pre-dialysis. *J Bras Nefrol* 2016; 38: 31–41
70. Godefroy O, Gibbons L, Diouf M *et al*. Validation of an integrated method for determining cognitive ability: implications for routine assessments and clinical trials. *Cortex* 2014; 54: 51–62
71. O’Lone E, Connors M, Masson P *et al*. Cognition in people with end-stage kidney disease treated with hemodialysis: a systematic review and meta-analysis. *Am J Kidney Dis* 2016; 67: 925–935

Received: 15.5.2021; Editorial decision: 24.6.2021